About Revolution Medicines, Inc. - Common Stock (RVMD)
Revolution Medicines Inc is a biotechnology company focused on developing innovative therapies to target difficult-to-treat cancers. The company is dedicated to advancing the field of precision medicine, leveraging its proprietary drug discovery platforms to explore new approaches to inhibit cancer-causing pathways. Through rigorous research and clinical trials, Revolution Medicines aims to bring forward novel treatments that not only address the complexities of tumor biology but also improve the effectiveness and safety of cancer care for patients. Their commitment to scientific excellence and collaboration positions them as a forward-thinking leader in the oncology space. Read More
Shares of Revolution Medicines, Inc. (NASDAQ: RVMD) traded at a new 52-week high today and are currently trading at $35.52. So far today, approximately 1.12M shares have been exchanged, as compared to an average 30-day volume of 1.43M shares.
As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Shares of Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced pricing of a $6 million public offering of shares at $0.14 per share.
Revolution Medicines announced the publication of a peer-reviewed research paper in "Cancer Discovery" detailing the discovery and preclinical to clinical translation for RMC-6236 on Monday. The company also announced the publication of two peer-reviewed research papers in "Nature" Tuesday. The first paper highlights the discovery and preclinical characterization of RMC-7977, and the second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC.
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.
Raymond James initiated coverage on Revolution Medicines Inc (NASDAQ: RVMD), noting that the October readout of RMC-6236 was compelling compared to historical SoC.
